ライフサイエンスコーパス: hormone replacement therapy

1 istics, risk factors, and therapy (including hormone replacement therapy).

2 adduct induced by equine estrogens used for hormone replacement therapy.

3 h can be effectively treated with the use of hormone replacement therapy.

4 ive, and evidence is emerging for the use of hormone replacement therapy.

5 one concentration or by the need for thyroid hormone replacement therapy.

6 ancy, while using oral contraceptives and/or hormone replacement therapy.

7 he administration of oral contraceptives and hormone replacement therapy.

8 Premarin is the most widely used formula for hormone replacement therapy.

9 eproductive-age women, and/or treatment with hormone replacement therapy.

10 e of HDL and other intermediate endpoints to hormone replacement therapy.

11 the keywords of menopause, sex steroids, and hormone replacement therapy.

12 To review the randomized trials of hormone replacement therapy.

13 y mass index, education, and (in women only) hormone replacement therapy.

14 otic events among postmenopausal women using hormone replacement therapy.

15 ysicians of the utility and safety of growth hormone replacement therapy.

16 at menopause, marital status, and the use of hormone replacement therapy.

17 presence of diabetes, and use of aspirin or hormone replacement therapy.

18 ausal women, regardless of whether they took hormone replacement therapy.

19 dex, physical activity level and duration of hormone replacement therapy.

20 ence in postmenopausal women who do not take hormone replacement therapy.

21 strogen-regulated malignancies, and even for hormone replacement therapy.

22 vely used by women as a contraceptive and in hormone replacement therapy.

23 g mechanism that represents a new option for hormone replacement therapy.

24 ted between SP risk and physical activity or hormone replacement therapy.

25 enzyme inhibitors, beta-blockers, and growth hormone replacement therapy.

26 oid, and sex steroid production that require hormone replacement therapy.

27 ls and bone health can be limited by focused hormone replacement therapy.

28 r history of aspirin, oral contraceptive, or hormone replacement therapy.

29 sis, and history of fracture, and (in women) hormone replacement therapy.

30 possibly because of interactions with age or hormone replacement therapy.

31 g medication, season, menopausal status, and hormone replacement therapy.

32 oductive cancers observed in women receiving hormone replacement therapy.

33 lism have not revealed any adverse effect of hormone-replacement therapy.

34 an augmented response of HDL cholesterol to hormone-replacement therapy.

35 malignancy, or with any contraindications to hormone-replacement therapy.

36 those who are postmenopausal or those taking hormone-replacement therapy.

37 te end point and among users and nonusers of hormone-replacement therapy.

38 ss, diet, physical activity, medication, and hormone-replacement therapy.

39 med from the search for safe alternatives to hormone replacement therapies.

40 ignaling component as a candidate target for hormone replacement therapies.

41 men; 2) post-menopausal women not receiving hormone replacement therapy; 3) pre-menopausal women not

42 /-44 mg/L; P<0.0001), women on versus not on hormone-replacement therapy (398+/-89 versus 291+/-60 mg

43 postmenopausal women who had never received hormone replacement therapy, a stronger positive associa

44 effect of the most widely used modalities of hormone replacement therapy against cardiovascular disea

45 sex, smoking, physical activity, menopause, hormone replacement therapy, alcohol, and aspirin use; a

46 ificantly greater than in those treated with hormone replacement therapy alone (4.2% [3.8] vs 3.0% [4

47 ex, diabetes, use of oral contraceptives and hormone replacement therapy among women, intake of vitam

48 nitiative and the ensuing drop in the use of hormone-replacement therapy among postmenopausal women i

49 Such exposures include estrogenic hormone replacement therapies and dietary and environmen

50 of postmenopausal (PMP) women were receiving hormone replacement therapy and 14%, bisphosphonate trea

51 eled the search for new androgens for use in hormone replacement therapy and as anabolic agents.

52 st cancer screening, the association between hormone replacement therapy and breast cancer incidence,

53 A recent investigation of hormone replacement therapy and breast cancer risk used

54 ith vascular factors (hypertension and BMI), hormone replacement therapy and depression.

55 lp resolve the current controversy regarding hormone replacement therapy and improve cardiovascular h

56 peutically to oppose the effect of E2 during hormone replacement therapy and in the treatment of uter

57 a synthetic progestin used in postmenopausal hormone replacement therapy and oral contraception, also

58 inical decision-making concerning the use of hormone replacement therapy and other novel estrogen ago

59 The association between menopausal hormone replacement therapy and ovarian cancer is unclea

60 Investigation of both hormone replacement therapy and premenopausal hormone us

61 de screening for prostate and breast cancer, hormone replacement therapy and risk for breast cancer,

62 ific mortality), overall and with respect to hormone replacement therapy and tamoxifen treatment.

63 een postulated to occur in women who receive hormone replacement therapy and/or by additional molecul

64 e transient excess incidence associated with hormone-replacement therapy and adjusting for trends in

65 en who were receiving and had never received hormone-replacement therapy and who were naturally match

66 ersonal history of breast cancer, and use of hormone replacement therapy) and mammographic findings r

67 These findings indicate that BMI, parity, hormone replacement therapy, and alcohol consumption may

68 pregnancies, use of oral contraceptives and hormone replacement therapy, and BRCA mutation status.

69 ld disease is possible with bisphosphonates, hormone replacement therapy, and calcimimetics.

70 They are selenium, calcium carbonate, hormone replacement therapy, and nonsteroidal anti-infla

71 l intake, type 2 diabetes and parity, use of hormone replacement therapy, and oral contraceptives in

72 min D measurement, menopausal status, use of hormone replacement therapy, and physical activity; P fo

73 9 %, 15.3 %, and 27.3 %) for postmenopausal, hormone replacement therapy, and premenopausal subjects,

74 was adjusted for nodal status, prior use of hormone replacement therapy, and prior chemotherapy (HR,

75 ter ovarian cancer treatment can safely take hormone-replacement therapy, and this may, in fact, infe

76 ceptives; 4) post-menopausal women receiving hormone replacement therapy; and 5) pre-menopausal women

77 g (AOR 1.569, 95% CI 1.292-1.905), or use of hormone replacement therapies (AOR 1.548, 95% CI 1.273-1

78 Other preventive measures such as hormone replacement therapy are also helpful.

79 on and scattering properties for women using hormone replacement therapy are intermediate between pre

80 o inform dosage and timing of antihormone or hormone replacement therapies as part of a personalized

81 candidates received calcium, vitamin D, and hormone replacement therapy as indicated for hypogonadis

82 graine with combined oral contraceptives and hormone replacement therapy, as well as the risk of isch

83 activity, alcohol intake, menopausal status, hormone replacement therapy, aspirin use, and dietary fa

84 Together, our findings suggest that hormone replacement therapy benefits cognitive aging, in

85 on of menopause, pretreatment assessment for hormone replacement therapy, benefits and risks of this

86 her CRP levels: age, gender (with or without hormone replacement therapy), body mass index >25 kg/m2,

87 menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, an

88 tabilized in subjects who were not receiving hormone replacement therapy but continued to decline in

89 e suggests the possibility of a benefit from hormone replacement therapy, but the optimal trial has y

90 menopausal symptoms and as an alternative to hormone replacement therapy, but they can produce potent

91 Combined hormone replacement therapy (CHRT) containing estrogens

92 Women using combined estrogen and progestin hormone replacement therapy (CHRT) have an increased ris

93 that use of combined estrogen and progestin hormone replacement therapy (CHRT) increases breast canc

94 Our results suggest that growth hormone replacement therapy could be protective against

95 If the observed associations are causal, hormone replacement therapy could have a role in prevent

96 Hormone replacement therapy did not affect the relative

97 icantly more prevalent among women receiving hormone replacement therapy during the previous year.

98 We have previously reported that estrogen/hormone replacement therapy (E/HRT) has beneficial effec

99 lean body mass, pulse rate, pulse pressure, hormone-replacement therapy, educational status, and phy

100 s no compelling evidence that postmenopausal hormone replacement therapy either decreases or increase

101 typic relative risks were affected by use of hormone replacement therapy, either overall or for oestr

102 from menstrual history, gynecologic surgery, hormone replacement therapy, follicle-stimulating hormon

103 Recent clinical trials of hormone replacement therapy for cardiovascular disease h

104 l management of a patient who is considering hormone replacement therapy for menopausal symptoms.

105 egnancy in the past 15 years, and the use of hormone replacement therapy for more than 4 years was as

106 nt practitioners to at least consider growth hormone replacement therapy for patients with definite g

107 a definitive statement can be made regarding hormone replacement therapy for women who have had stage

108 zed controlled trials in which no benefit of hormone-replacement therapy for postmenopausal women has

109 e active components in the widely prescribed hormone replacement therapy formulation Premarin.

110 Growth hormone replacement therapy (GHRT) may significantly imp

111 diabetes mellitus, and hypertension, whereas hormone replacement therapy had no effect on progression

112 Menopausal hormone replacement therapy has been widely used to alle

113 Understanding why hormone replacement therapy has beneficial effects on in

114 The controversy surrounding hormone replacement therapy has induced fear in patients

115 Hormone replacement therapy has not been shown to benefi

116 ies suggest that postmenopausal women taking hormone replacement therapy have a reduced risk of radio

117 and breast cancer among women randomized to hormone replacement therapy have increased interest in o

118 Changes in lipoproteins in response to hormone-replacement therapy have now been analysed for b

119 ors were not increased by use of any form of hormone replacement therapy; however, small numbers of t

120 drugs (HR, 1.25; 95% CI, 1.08 to 1.43), and hormone replacement therapy (HR, 1.27; 95% CI, 1.08 to 1

121 (0.6%) as well as postmenopausal women with hormone replacement therapy (HRT) (0.5%).

122 reas those postmenopausal women who had used hormone replacement therapy (HRT) (primarily estrogen) h

123 of concerns and controversy about the use of hormone replacement therapy (HRT) after oophorectomy.

124 Many premenopausal women choose to take hormone replacement therapy (HRT) after undergoing BPO t

125 Twenty-six women were receiving hormone replacement therapy (HRT) and 43 were untreated

126 Hormone replacement therapy (HRT) and antioxidant vitami

127 This year's work on hormone replacement therapy (HRT) and cardiovascular dis

128 ed the association between the initiation of hormone replacement therapy (HRT) and early cardiac even

129 search has examined the relationship between hormone replacement therapy (HRT) and pulmonary function

130 Little is known about hormone replacement therapy (HRT) and risk for myocardia

131 ether with the epidemiological evidence that hormone replacement therapy (HRT) and, less consistently

132 Long-term, postmenopausal use of hormone replacement therapy (HRT) appears to increase br

133 ovarian cycle, pregnancy and with exogenous hormone replacement therapy (HRT) are currently unknown.

134 ted and often conflicting data on the use of hormone replacement therapy (HRT) as a possible risk fac

135 777 of 1914 women (40.6%) who used hormone replacement therapy (HRT) before trial entry dev

136 pausal women and women who consistently took hormone replacement therapy (HRT) between menopause and

137 Basic neuroscience findings suggest that hormone replacement therapy (HRT) could reduce a woman's

138 e clinical trials provoked major debate when hormone replacement therapy (HRT) did not reduce coronar

139 Recent clinical trials demonstrating that hormone replacement therapy (HRT) does not prevent coron

140 Sex and hormone replacement therapy (HRT) effects on the distrib

141 ntinues to be conducted on the mechanisms of hormone replacement therapy (HRT) effects, and the first

142 pproximately 10 million women were receiving hormone replacement therapy (HRT) for alleviation of men

143 Postmenopausal hormone replacement therapy (HRT) has been shown to elev

144 Initiation of hormone replacement therapy (HRT) has been shown to incr

145 Over the past few decades hormone replacement therapy (HRT) has been used increasi

146 The advantages and disadvantages of hormone replacement therapy (HRT) have been debated near

147 ding to follow-up time, severity, and use of hormone replacement therapy (HRT) in a retrospective ana

148 nships among breast density, age, and use of hormone replacement therapy (HRT) in breast cancer detec

149 The role of hormone replacement therapy (HRT) in lung cancer develop

150 Hormone replacement therapy (HRT) increases the risk of

151 Although hormone replacement therapy (HRT) is an established appr

152 We sought to determine whether hormone replacement therapy (HRT) is associated with an

153 Prolonged postmenopausal hormone replacement therapy (HRT) is associated with inc

154 Hormone replacement therapy (HRT) is frequently prescrib

155 nsent to breast cancer survivors considering hormone replacement therapy (HRT) is offered.

156 Hormone replacement therapy (HRT) is typically withheld

157 Hormone replacement therapy (HRT) is widely considered t

158 Although postmenopausal hormone replacement therapy (HRT) is widely used in the

159 Hormone replacement therapy (HRT) is widely used to mana

160 or absence of oestrogen and selective use of hormone replacement therapy (HRT) may alter these relati

161 en with clinically recognized heart disease, hormone replacement therapy (HRT) may be associated with

162 It has been hypothesized that postmenopausal hormone replacement therapy (HRT) may increase levels of

163 Hormone replacement therapy (HRT) may reduce lung cancer

164 Some observational data suggest that hormone replacement therapy (HRT) may reduce the risk of

165 of menopausal status, age, race, and use of hormone replacement therapy (HRT) on 3-year changes in g

166 Furthermore, the effects of statins plus hormone replacement therapy (HRT) on cardiovascular outc

167 oximately 20%) who have augmented effects of hormone replacement therapy (HRT) on levels of HDL chole

168 gate whether female reproductive history and hormone replacement therapy (HRT) or birth control pills

169 Studies of long-term hormone replacement therapy (HRT) suggest an associated

170 omy produce relative risks for the effect of hormone replacement therapy (HRT) that are biased downwa

171 ostmenopausal women in the United States use hormone replacement therapy (HRT) to treat symptoms of m

172 est the model and to estimate the effects of hormone replacement therapy (HRT) use and smoking.

173 A significant interaction between hormone replacement therapy (HRT) use and tumor hormone

174 Increased duration of hormone replacement therapy (HRT) use in quartiles was a

175 Postmenopausal hormone replacement therapy (HRT) use is common in the U

176 nd measures of obesity and fat distribution, hormone replacement therapy (HRT) use, and serum sex hor

177 After excluding women with a history of hormone replacement therapy (HRT) use, the authors condu

178 it-dialing controls regarding postmenopausal hormone replacement therapy (HRT) use.

179 at differentiate long-term (> or = 10 years) hormone replacement therapy (HRT) users from short-term

180 were not and 31 women were taking long-term hormone replacement therapy (HRT) using estrogen either

181 xamination, responded to questions regarding hormone replacement therapy (HRT), and provided a blood

182 as a component in both contraceptives and in hormone replacement therapy (HRT), both on their own and

183 Among men and women not using hormone replacement therapy (HRT), CRP levels were signi

184 Because of widespread clinical use of hormone replacement therapy (HRT), it is critical to und

185 n to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumul

186 Hormone replacement therapy (HRT), the mainstay of osteo

187 were receiving long-term glucocorticoids and hormone replacement therapy (HRT).

188 een reduced in postmenopausal women who take hormone replacement therapy (HRT).

189 vels among postmenopausal controls not using hormone replacement therapy (HRT).

190 genous hormone levels, influences the use of hormone replacement therapy (HRT).

191 that women be counseled about postmenopausal hormone replacement therapy (HRT).

192 estinal motility; both are key components of hormone replacement therapy (HRT).

193 E(2) may be related to beneficial effects of hormone replacement therapy (HRT).

194 of ovarian cancer associated with the use of hormone replacement therapy (HRT).

195 d 140 postmenopausal women-31 not taking any hormone replacement therapy (HRT); 75 taking estrogen al

196 1.32; 95% CI, 1.02 to 1.70), current use of hormone replacement therapy (HRT; OR, 1.84; 95% CI, 1.38

197 Hormone-replacement therapy (HRT) has been available for

198 Current use of hormone-replacement therapy (HRT) increases the incidenc

199 me vigorous activity, vegetable consumption, hormone-replacement therapy (HRT), and estrogen exposure

200 ovascular risk may be modified by concurrent hormone replacement therapy (HT).

201 ized that the progesterone component of some hormone replacement therapies in women is detrimental to

202 his observation highlights the importance of hormone replacement therapy in postmenopausal conditions

203 ovascular risks associated with conventional hormone replacement therapy in postmenopausal women (5-7

204 cancer epidemiology also support a role for hormone replacement therapy in prevention of colorectal

205 eplacement Study (HERS), studied the role of hormone replacement therapy in protecting women from cor

206 e associated with a differential response to hormone replacement therapy in several domains of estrog

207 n, underscores the unexplored utility of GCC hormone replacement therapy in the chemoprevention of co

208 an odor memory/discrimination task and that hormone replacement therapy in the menopause may be an e

209 The association was not modified by hormone replacement therapy in women or physical activit

210 Treatment intensity for diabetes and use of hormone replacement therapy in women were similar across

211 atial learning and may have implications for hormone replacement therapy in women.

212 nal level, smoking, alcohol consumption, and hormone replacement therapy (in women), the upper quarti

213 n-users (age 58 +/- 1 years) and 32 users of hormone replacement therapy, including oestrogen alone (

214 Crucially, oral but not transdermal hormone-replacement therapy increases activated protein

215 re prevented with estrogen (E(2))-containing hormone replacement therapy initiated shortly following

216 Hormone replacement therapy is associated with a marked

217 Hormone replacement therapy is contraindicated in patien

218 There are no data to suggest that hormone replacement therapy is contraindicated in women

219 However, hormone replacement therapy is demonstrated to increase

220 Hormone replacement therapy is effective but is not with

221 ical cardiovascular events in the setting of hormone replacement therapy is not yet known.

222 Hormone replacement therapy is often either undesirable

223 Thyroid hormone replacement therapy is used not only to rectify

224 ion concerning the cardiovascular effects of hormone replacement therapy is whether genetic factors c

225 ystemic estrogen replacement (in the form of hormone replacement therapy) is able to accelerate heali

226 tional data that excluded prevalent users of hormone replacement therapy led to attenuated discrepanc

227 Together, our data suggest that hormone replacement therapy may benefit cognitive aging,

228 e on various health outcomes associated with hormone replacement therapy may differ.

229 essed whether different oral progestogens in hormone replacement therapy may differentially affect th

230 on health and cognitive status, suggest that hormone-replacement therapy may have a selective benefic

231 001), were lower among women currently using hormone replacement therapy (mean 0.98 mg/l vs. 1.23 mg/

232 for age, Tyrer-Cuzick risk, smoking, use of hormone replacement therapy, menopausal status, baseline

233 sion suggest that combined estrogen/androgen hormone replacement therapy might reduce the risk of bre

234 e younger at enrollment (P < 0.001) and used hormone replacement therapy more often (P < 0.003).

235 ndrome in postmenopausal US women not taking hormone replacement therapy (n=362) in a prevalent case-

236 estrogen alone (E; n = 30), and a third [non-hormone replacement therapy (NHRT; n = 62)] control grou

237 adjusted for age, body-mass index, previous hormone-replacement therapy, nodal status, tumour size,

238 ship was present among men, women not taking hormone replacement therapy, nonsmokers, and those indiv

239 or modulator (SERM) therapy (n = 8), and no (hormone replacement) therapy (NT) (n = 23).

240 e gain was present only among never users of hormone replacement therapy (odds ratio (OR) = 2.02 (95%

241 ncies regarding the effect of postmenopausal hormone replacement therapy on coronary heart disease.

242 e found that the impact of the withdrawal of hormone replacement therapy on density reduction was lar

243 The independent effect of hormone replacement therapy on development of cytologic

244 The effects of hormone-replacement therapy on cardiovascular risk facto

245 The effect of hormone-replacement therapy on inflammatory markers and

246 r alpha (ER-alpha) may modify the effects of hormone-replacement therapy on levels of high-density li

247 rmed the putative antiatherogenic effects of hormone-replacement therapy on lipoprotein metabolism.

248 e receiving and those who had never received hormone-replacement therapy on measures of verbal memory

249 This study examined the effects of hormone-replacement therapy on memory and other cognitiv

250 rdiovascular disease and cancer, and without hormone replacement therapy or lipid-lowering medication

251 en SLE and current use or duration of use of hormone replacement therapy or oral contraceptives, and

252 Use of tamoxifen combined with hormone replacement therapy or use of raloxifene, any ar

253 Hormone replacement therapy (OR = 2.25, 95% CI: 1.40, 3.

254 te intake), lifestyle habits (such as use of hormone replacement therapy), or biological characterist

255 djustment for age, BMI, BMD, and past use of hormone replacement therapy, or when NTx and CTx values

256 ificantly increased for women who used prior hormone replacement therapy (P = .007) or received prior

257 ynamic management, endocrine dysfunction and hormone replacement therapy, pediatric donor management,

258 The women receiving hormone-replacement therapy performed significantly bett

259 model assessment of insulin resistance, and hormone replacement therapy, premature menopause was ass

260 lycystic ovarian syndrome who was undergoing hormone replacement therapy presented with a 6-month his

261 merous clinical and animal studies show that hormone replacement therapy reduces the risk of colon tu

262 en/Progestin-Replacement Study data suggests hormone-replacement therapy reduces the risk of developi

263 Estrogens used in hormone replacement therapy regimens may increase the ri

264 Appropriate hormone replacement therapy reinstating the oscillatory

265 largely limited to women who were not taking hormone replacement therapy (relative risk, 2.60; 95% CI

266 ng information about oral contraceptive use, hormone replacement therapy, reproductive history, sun e

267 smoking, diabetes mellitus, body mass index, hormone replacement therapy, serum creatinine, and the u

268 Thus, the decision to use hormone replacement therapy should be made jointly by ea

269 Hormone replacement therapy should not be initiated for

270 Women's Health Initiative, however, are that hormone replacement therapy should not be used for prima

271 weight, height, menopausal status or use of hormone replacement therapy, socioeconomic status, and p

272 contraceptive pill use, surgical menopause, hormone replacement therapy, statins, acetaminophen/para

273 n increase in the HDL cholesterol level with hormone-replacement therapy that was more than twice the

274 Among the identified risks and benefits of hormone-replacement therapy, the effects of treatment on

275 vels of blood pressure, and use or nonuse of hormone-replacement therapy, the relative risks of first

276 Clinical studies of hormone replacement therapy to prevent cardiovascular di

277 ere seems to be little if any risk in giving hormone replacement therapy to women who have had breast

278 Despite the outcome of the hormone-replacement therapy trials, recent work has conf

279 Although menopausal status and hormone replacement therapy use dominate women's bone he

280 LDL, HDL, C-reactive protein, hormone replacement therapy use, and diabetes duration d

281 Late age at menarche, hormone replacement therapy use, and Hispanic race were

282 ness, single vitamin/mineral supplement use, hormone replacement therapy use, and smoking status.

283 ts were seen for smoking, physical activity, hormone replacement therapy use, multiparity, or hand OA

284 age at first birth, breastfeeding, menarche, hormone replacement therapy use, somatotype at age 18, b

285 ince over 90% of this group had a history of hormone replacement therapy use, the finding that years

286 fter stratification by smoking status and by hormone replacement therapy use, two factors known to in

287 ody mass index, time since menopause, use of hormone replacement therapy, use of calcium supplements,

288 t for potential confounders and exclusion of hormone replacement therapy users had little impact.

289 Whether menopausal hormone replacement therapy using a combined estrogen-pr

290 Doses and routes of hormone replacement therapy vary by indication.

291 Current use of hormone replacement therapy was associated with signific

292 iteal (p < 0.05) intimal-medial thicknesses, hormone replacement therapy was associated with thinner

293 Only among women who had never used hormone replacement therapy was the risk of endometrial

294 Oral contraceptive use and hormone replacement therapy were not associated with mel

295 ) age of 61 +/- 11 y, who were not receiving hormone replacement therapy, were fed eucaloric diets to

296 ells would be a significant improvement over hormone replacement therapies, which incur side effects

297 pecific mortality among women who never used hormone replacement therapy, who never smoked, and who e

298 regarding uterine preservation and post-RRSO hormone replacement therapy will be addressed.

299 Hormone replacement therapy with estrogen has been repor

300 The standard treatment is thyroid hormone replacement therapy with levothyroxine.